| Facilitators and barriers to the implementation of the HPV VACs (vaccinate adolescents against cancers) program: a consolidated framework for implementation research analysis C Escoffery Preventing Chronic Disease 16, 2019 | 50 | 2019 |
| A randomized controlled trial of a 6-month low-carbohydrate intervention on disease progression in men with recurrent prostate cancer: carbohydrate and prostate study 2 (CAPS2) SJ Freedland, J Allen, A Jarman, T Oyekunle, AJ Armstrong, JW Moul, ... Clinical Cancer Research 26 (12), 3035-3043, 2020 | 44 | 2020 |
| Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk J Xiao, L Howard, J Wan, E Wiggins, A Vidal, P Cohen, SJ Freedland Oncotarget 8 (55), 94900, 2017 | 38 | 2017 |
| Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy AC Vidal, LE Howard, E Wiggins, AM De Hoedt, SL Shiao, S Knott, ... Cancer epidemiology 62, 101578, 2019 | 21 | 2019 |
| UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression DJ Grant, Z Chen, LE Howard, E Wiggins, A De Hoedt, AC Vidal, ... BMC cancer 17, 1-8, 2017 | 20 | 2017 |
| Soluble endoglin (sCD105) as a novel biomarker for detecting aggressive prostate cancer AC Vidal, F Duong, LE Howard, E Wiggins, SJ Freedland, NA Bhowmick, ... Anticancer research 40 (3), 1459-1462, 2020 | 15 | 2020 |
| Diagnostic utility of serum and urinary metabolite analysis in patients with interstitial cystitis/painful bladder syndrome J Kim, A De Hoedt, E Wiggins, K Haywood, P Jin, B Greenwood, ... Urology 157, 85-92, 2021 | 9 | 2021 |
| Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial EK Wiggins, T Oyekunle, LE Howard, SC Markt, LA Mucci, DL Bliwise, ... The Prostate 80 (15), 1304-1313, 2020 | 9 | 2020 |
| Racial differences in circulating mitochondria‐derived peptides may contribute to prostate cancer health disparities A Ramirez‐Torres, AL Reagan, LE Howard, E Wiggins, AC Vidal, J Wan, ... The Prostate 82 (13), 1248-1257, 2022 | 6 | 2022 |
| Family history of prostate cancer and prostate tumor aggressiveness in black and non-black men; results from an equal access biopsy study KR Jenkins, T Oyekunle, LE Howard, EK Wiggins, SJ Freedland, EH Allott Cancer Causes & Control 32, 337-346, 2021 | 6 | 2021 |
| Metabolic syndrome is associated with aggressive prostate cancer regardless of race L Guerrios-Rivera, LE Howard, EK Wiggins, C Hoyo, DJ Grant, ... Cancer Causes & Control 34 (3), 213-221, 2023 | 3 | 2023 |
| Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system EM Anderson, L Gu, T Oyekunle, AM De Hoedt, E Wiggins, CJ Gay, DJ Lu, ... Prostate Cancer and Prostatic Diseases 25 (3), 593-595, 2022 | 3 | 2022 |
| The impact of the social construct of race on outcomes among bacille Calmette‐Guérin‐treated patients with high‐risk non‐muscle–invasive bladder cancer in an equal‐access setting C Lawler, L Gu, LE Howard, B Branche, E Wiggins, A Srinivasan, ... Cancer 127 (21), 3998-4005, 2021 | 3 | 2021 |
| Racial differences in circulating mitochondria-derived peptides may contribute to prostate cancer health disparities A Ramirez-Torres, AL Reagan, LE Howard, E Wiggins, AC Vidal, J Wang, ... Cancer Research 80 (16_Supplement), 3511-3511, 2020 | 1 | 2020 |
| PD30-09 randomized controlled trial of a 6-month low carbohydrate intervention on weight and disease progression in men with recurrent prostate cancer: Carbohydrate and … S Freedland, J Allen, A Jarman, T Oyekunle, A Armstrong, J Moul, ... The Journal of Urology 201 (Supplement 4), e563-e563, 2019 | 1 | 2019 |
| Peer reviewed: Facilitators and barriers to the implementation of the HPV VACs (vaccinate adolescents against cancers) program: A consolidated framework for implementation … C Escoffery, K Riehman, L Watson, AS Priess, MF Borne, SN Halpin, ... Preventing Chronic Disease 16, 2019 | 1 | 2019 |
| Impact of race on outcomes among BCG-treated high-risk non-muscle invasive bladder cancer patients in an equal access setting C Lawler, L Howard, E Wiggins, Z Klaassen, A Dehoedt, S Freedland, ... European Urology Open Science 33, S364, 2021 | | 2021 |
| MP62-18 ATENOLOL IS ASSOCIATED WITH REDUCED RISK OF PROSTATE CANCER UPGRADING: A MULTICENTER RETROSPECTIVE STUDY A Zahalka, E Fram, L Howard, E Garden, L Mohn, J Annam, A Reagan, ... Journal of Urology 206 (Supplement 3), e1099-e1100, 2021 | | 2021 |
| MP26-19 FURTHER DEFINING THE NATURAL HISTORY OF BIOCHEMICAL PROGRESSION FOLLOWING RADICAL PROSTATECTOMY: DOES PSA DOUBLING TIME CHANGE WITH TIME? J Parrish, J Janes, E Wiggins, C Amling, W Aronson, M Cooperberg, ... Journal of Urology 206 (Supplement 3), e471, 2021 | | 2021 |
| MP67-11 DOES EQUAL ACCESS MEAN EQUAL TREATMENT? RACE AND TREATMENT RECEIVED IN AN EQUAL ACCESS MEDICAL CENTER A Freedland*, L Howard, AC Vidal, EK Wiggins, AMD Hoedt, S Freedland The Journal of Urology 203 (Supplement 4), e1029-e1029, 2020 | | 2020 |
